Dr. Reddy's Laboratories ...

12.37
-0.87 (-6.57%)
At close: Apr 04, 2025, 3:59 PM
12.36
-0.04%
After-hours: Apr 04, 2025, 05:35 PM EDT

Dr. Reddy's Laboratories Statistics

Share Statistics

Dr. Reddy's Laboratories has 833.15M shares outstanding. The number of shares has increased by 0.06% in one year.

Shares Outstanding 833.15M
Shares Change (YoY) 0.06%
Shares Change (QoQ) 0.01%
Owned by Institutions (%) 14.2%
Shares Floating 833.13M
Failed to Deliver (FTD) Shares 127
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 13.11M, so 1.57% of the outstanding shares have been sold short.

Short Interest 13.11M
Short % of Shares Out 1.57%
Short % of Float 1.57%
Short Ratio (days to cover) 8.66

Valuation Ratios

The PE ratio is 18.45 and the forward PE ratio is 0.19. Dr. Reddy's Laboratories's PEG ratio is 0.8.

PE Ratio 18.45
Forward PE 0.19
PS Ratio 3.68
Forward PS 0
PB Ratio 3.66
P/FCF Ratio 57.09
PEG Ratio 0.8
Financial Ratio History

Enterprise Valuation

Dr. Reddy's Laboratories has an Enterprise Value (EV) of 1,040.3B.

EV / Sales 3.73
EV / EBITDA 11.77
EV / EBIT 22.9
EV / FCF 57.8

Financial Position

The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.07.

Current Ratio 2.58
Quick Ratio 1.92
Debt / Equity 0.07
Debt / EBITDA 0.23
Debt / FCF 1.11
Interest Coverage 39.58

Financial Efficiency

Return on Equity is 19.85% and Return on Invested Capital is 17.18%.

Return on Equity 19.85%
Return on Assets 14.37%
Return on Invested Capital 17.18%
Revenue Per Employee $10.32M
Profits Per Employee $2.06M
Employee Count 27,048
Asset Turnover 0.72
Inventory Turnover 1.82

Taxes

Income Tax 16.19B
Effective Tax Rate 22.52%

Stock Price Statistics

The stock price has increased by -16.14% in the last 52 weeks. The beta is 0.48, so Dr. Reddy's Laboratories's price volatility has been higher than the market average.

Beta 0.48
52-Week Price Change -16.14%
50-Day Moving Average 13.34
200-Day Moving Average 14.94
Relative Strength Index (RSI) 29.36
Average Volume (20 Days) 1.98M

Income Statement

In the last 12 months, Dr. Reddy's Laboratories had revenue of 279.16B and earned 55.68B in profits. Earnings per share was 66.8.

Revenue 279.16B
Gross Profit 163.61B
Operating Income 67.73B
Net Income 55.68B
EBITDA 88.42B
EBIT 73.58B
Earnings Per Share (EPS) 66.8
Full Income Statement

Balance Sheet

The company has 7.11B in cash and 20.02B in debt, giving a net cash position of -12.91B.

Cash & Cash Equivalents 7.11B
Total Debt 20.02B
Net Cash -12.91B
Retained Earnings 265.26B
Total Assets 481.06B
Working Capital 121.07B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 45.43B and capital expenditures -27.43B, giving a free cash flow of 18B.

Operating Cash Flow 45.43B
Capital Expenditures -27.43B
Free Cash Flow 18B
FCF Per Share 21.59
Full Cash Flow Statement

Margins

Gross margin is 58.61%, with operating and profit margins of 24.26% and 19.95%.

Gross Margin 58.61%
Operating Margin 24.26%
Pretax Margin 25.74%
Profit Margin 19.95%
EBITDA Margin 31.67%
EBIT Margin 24.26%
FCF Margin 6.45%

Dividends & Yields

RDY pays an annual dividend of $0.48, which amounts to a dividend yield of 2.97%.

Dividend Per Share $0.48
Dividend Yield 2.97%
Dividend Growth (YoY) -1.74%
Payout Ratio 63.89%
Earnings Yield 5.42%
FCF Yield 1.75%
Dividend Details

Analyst Forecast

The average price target for RDY is $17, which is 37.4% higher than the current price. The consensus rating is "Buy".

Price Target $17
Price Target Difference 37.4%
Analyst Consensus Buy
Analyst Count 1
Stock Forecasts

Stock Splits

The last stock split was on Nov 5, 2024. It was a forward split with a ratio of 5:1.

Last Split Date Nov 5, 2024
Split Type forward
Split Ratio 5:1

Scores

Altman Z-Score 2.36
Piotroski F-Score 4